Management of HLA-B27 Positive Adolescents

Screening and Monitoring Recommendations

The American College of Rheumatology recommends that adolescents with HLA-B27 positivity should be considered at moderate risk for uveitis, particularly those with enthesitis-related arthritis, and require ophthalmologic screening every 6-12 months 1, 2
Education regarding warning signs of acute anterior uveitis (eye pain, redness, photophobia) is strongly recommended to decrease delay in treatment and reduce complications 3, 4
If diagnosed with uveitis, monitoring should occur no less frequently than every 3 months while on stable therapy 1
More frequent monitoring (within 1 month after changes in topical glucocorticoids or within 2 months after changes in systemic therapy) is strongly recommended for those with diagnosed uveitis 2

A complete rheumatologic history and examination of all peripheral joints for tenderness, swelling, and range of motion; examination of the spine is necessary 5
For chronic back pain (>3 months) with onset before age 45, assess for inflammatory characteristics including morning stiffness, nocturnal/early morning pain, and improvement with exercise 6, 7

HLA-B27 testing should be used as a screening parameter rather than a definitive diagnostic test 7
Approximately 30-40% of patients with chronic back pain and positive HLA-B27 ultimately receive an ankylosing spondylitis diagnosis 7
Consider imaging (radiography or MRI) to evaluate for sacroiliitis in patients with suspected axial spondyloarthritis 6, 7

First-line treatment for arthritis/spondyloarthritis: NSAIDs at full dose, regardless of HLA-B27 status 6
Short-term use of NSAIDs is safe if inflammatory bowel disease is in remission, but long-term use or use in active IBD carries risk of worsening symptoms 8
For patients with active disease despite NSAIDs, TNF inhibitors (adalimumab, infliximab) are recommended as first-line biologics 6
For acute anterior uveitis, topical glucocorticoids are recommended as first-line treatment without immediate changes to systemic therapy 3, 4

Patients with inflammatory arthritis should be monitored with serial rheumatologic examinations, including inflammatory markers, every 4–6 weeks after treatment is instituted 5
MRI of the spine or pelvis may help evaluate disease activity when clinical assessment is uncertain 6